NCT05033145View on ClinicalTrials.gov

Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
COVID-19
Interventions
DRUG

AZVUDINE

AZVUDINE 5 tablets QD + standard treatment, for up to 14 days

DRUG

AZVUDINE placebo

5 tablets QD + standard treatment, for up to 14 days

Trial Locations (7)

Unknown

Hospital Moacyr Gomes de Azevedo, Cambuci

Hospital Santa Casa de Misericórdia de Campos, Campos dos Goytacazes

Unidade de Pesquisa Clínica / Centro de Alta Complexidade, Campos dos Goytacazes

Unidade Pré Hospitalar São José, Campos dos Goytacazes

Hospital de Itaocara, Itaocara

Hospital Armando Vidal, São Fidelis

28110-000

Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute, Campos dos Goytacazes

Sponsors
All Listed Sponsors
collaborator

GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil

UNKNOWN

collaborator

Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute

UNKNOWN

lead

HRH Pharmaceuticals Limited

OTHER

NCT05033145 - Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected) | Biotech Hunter | Biotech Hunter